Screener
Odyssey Therapeutics ODTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of marketable securities | (246,489) | - |
| Proceeds from sale of property and equipment | 281 | 138 |
| Purchases of property and equipment | (334) | (956) |
| Net cash (used in) provided by investing activities | (176,642) | 57,432 |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of common stock options | 1,237 | 235 |
| Proceeds from the exercise of common stock warrants | — | 6 |
| Principal payments on finance leases | (70) | (70) |
Item 1. Financial Statements.
FAQ
- What is Odyssey Therapeutics's investing cash flow?
- Odyssey Therapeutics (ODTX) reported investing cash flow of -$211.44M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Odyssey Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude